CELLECT BIOTECH/S (NASDAQ:APOP) shares saw unusually-strong trading volume on Monday . Approximately 10,569,155 shares were traded during trading, an increase of 3,967% from the previous session’s volume of 259,868 shares.The stock last traded at $0.58 and had previously closed at $0.41.
Separately, ValuEngine raised CELLECT BIOTECH/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
The company’s 50-day moving average is $0.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.47 and a quick ratio of 5.47.
A hedge fund recently bought a new stake in CELLECT BIOTECH/S stock. Wedbush Securities Inc. bought a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $66,000. Wedbush Securities Inc. owned approximately 1.19% of CELLECT BIOTECH/S as of its most recent SEC filing. Institutional investors own 5.07% of the company’s stock.
About CELLECT BIOTECH/S (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Further Reading: Bar Chart
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.